What Happened

AbbVie announced the acquisition of Apogee Therapeutics, a late-stage immunology biotech, signaling renewed big pharma interest in clinical-stage assets. This deal has put Syndax Pharmaceuticals, Viking Therapeutics, and Nektar Therapeutics on Wall Street's M&A watchlists.

Who Is Affected

Syndax Pharmaceuticals (SNDX) is the most likely target due to its two FDA-approved drugs, revenue growth, and existing partnership with Incyte. Viking Therapeutics (VKTX) and Nektar Therapeutics (NKTR) are also in focus but face higher market caps or longer timelines.

Market Impact

• Syndax: $1.71B market cap, 224% revenue growth, Incyte as logical acquirer
• Viking: $3.76B market cap, GLP-1/GIP obesity drug in Phase 3
• Nektar: $2.22B market cap, immunology asset heading to Phase 3

What to Watch

Monitor Syndax's Q2 earnings and Incyte's partnership moves, as these could trigger a bid. Viking's Phase 3 data and Nektar's funding runway are secondary catalysts.